Shots:

• The P-III (JUPITER-06) study evaluates toripalimab + TP vs PBO + TP in a ratio (1:1) in 514 patients with advanced or metastatic ESCC at 72 centers across China
• The trial met its co-primary EPs i.e., improvement in OS & PFS, m-OS (17mos. vs 11mos.), 1yr. OS rates (66.0% vs 43.7%), m-PFS (5.7mos. vs 5.5mos.), 1yr. PFS rates (27.8% vs 6.1%), PFS & OS benefits were observed across all PD-L1 expression subgroups, including in patients with low PD-L1 expression
• The incidence of grade >3 TEAEs was similar b/w both arms, 99.2% of patients experienced 1 TEAE with no new safety signals. The company plan to file an additional toripalimab’s BLAs with the US FDA over the next 3yrs. for other cancer

Ref: Globe Newswire | Image: PR Newswire